Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Why Investors Should Watch Teva Despite Regional Risks
12:52pm, Friday, 23'rd May 2025
Despite the lack of cautious enthusiasm from retail investors in Teva, it continues to beat consensus estimates by wide margins and has once again raised its 2025 financial guidance. I highlight Auste
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
05:22pm, Tuesday, 20'th May 2025
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approxim
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
04:30pm, Tuesday, 20'th May 2025
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
04:52am, Monday, 19'th May 2025
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior n
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
04:52am, Monday, 19'th May 2025
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purc
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
06:12pm, Thursday, 15'th May 2025
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
05:02pm, Monday, 12'th May 2025
A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (TEVA 5.82%) well higher on Monday. The company, known for being a top producer of g
Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside
11:33am, Thursday, 08'th May 2025
Teva's betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management's $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Re
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
08:50am, Thursday, 08'th May 2025
TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.
Why Teva Pharmaceutical Stock Is Soaring Today
02:08pm, Wednesday, 07'th May 2025
Shares of Teva Pharmaceutical (TEVA 8.44%) are surging on Wednesday. The company's stock is up 9.2% as of 1:15 p.m.
Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says
01:01pm, Wednesday, 07'th May 2025
The drugmaker reported first-quarter earnings that beat expectations and raised its full-year guidance.
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
12:13pm, Wednesday, 07'th May 2025
Teva Pharmaceutical Industries Ltd TEVA stock is trading higher on Wednesday after the company's first-quarter 2025 financial results. Here are the details.
Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties
11:51am, Wednesday, 07'th May 2025
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, any pharma shortages in the U.S., and much more.
Teva Pharma climbs as earnings impress
11:34am, Wednesday, 07'th May 2025
Shares in Teva Pharmaceutical Industries (NASDAQ:TEVA) rose 5% after publishing first-quarter earnings, where the Israeli company said US tariffs are expected to have an "immaterial impact". The T
